Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-23

Clinical Trial Update: Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety, tolerability, and pharmacokinetics of TRK-250 in idiopathic pulmonary fibrosis completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRK-250

Snippet

Sponsor: Toray Industries, Inc | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: COMPLETED | Results posted: 2023-10-23